Study shows how oncology practices change after durvalumab approval for unresectable stage III NSCLC patients

A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.

Generated by Feedzy